This blend puts 12 mg of tesamorelin and 3 mg of ipamorelin in one vial, a 4:1 GHRH to GHRP ratio.
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
Tesamorelin / Ipamorelin Blend is 2 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
Tesamorelin12 mg per vial
Ipamorelin3 mg per vial
What published studies and recent community write-ups report about amounts, timing and course length. 4 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Community-reported4 rows | |||||
| Community guide: 10/3 vial, 1 mg plus 300 mcg before bed | 1 mg tesamorelin plus 300 mcg ipamorelin (20 units of a 10/3 vial in 2 mL); 0.5 mg plus 150 mcg (10 units) as the lower step | Once daily in the evening before bed, 5 days on and 2 off; some split into morning and evening halves | Subcutaneous, abdomen, rotating sites | 8 weeks on8 weeks off, plus 2 days off each week | Community resource2026 |
| Written for the 10 mg / 3 mg vial: 2 mL of bacteriostatic water gives 5 mg/mL tesamorelin and 1.5 mg/mL ipamorelin, so every 10 units carries 0.5 mg and 150 mcg. The same 20-unit draw from this page's 12/3 vial in 2 mL is 1.2 mg tesamorelin with the same 300 mcg ipamorelin, so the tesamorelin side moves with the label. The guide says the 5-on/2-off rhythm and 8-week cycles are community consensus with no trial behind them and that the combination has no human trial data. Published April 2026. | |||||
| Community planning guide: 10/3 and 5/5 vials in 3 mL, stepped by 10 units | 10 units (0.1 mL) of a 10/3 vial in 3 mL gives about 333 mcg tesamorelin and 100 mcg ipamorelin; 20 units about 667 and 200 mcg; 30 units about 1 mg and 300 mcg | Once daily, usually in the evening | Subcutaneous | 8-16 weeksNot described | Community resource2026 |
| Describes two vendor vials (10/3 and 5/5) made up with 3.0 mL for 4.33 or 3.33 mg/mL in total, a step-up from 10 to 20 to 30 units, and a vial lasting 7-15 days at typical 20-40 unit draws. It cites the tesamorelin label doses (2 mg a day for the original Egrifta, 1.28 mg for Egrifta WR) and 100-300 mcg per dose for ipamorelin as its reference points and says plainly that no human trial has tested the two together. Last reviewed August 2026. | |||||
| Clinic guide: about 1 mg tesamorelin with 100-300 mcg ipamorelin, fasted at bedtime | About 1 mg tesamorelin plus 100-300 mcg ipamorelin per injection (tesamorelin given as a 1-2 mg a day range) | Once daily before bed on an empty stomach; some protocols add a morning dose | Subcutaneous, insulin syringe | 8-12 weeks5 days on and 2 off within the cycle, then a break | Community resource2026 |
| A Beverly Hills clinic's page describing the blend as a supervised, off-label therapy: a 2-hour fasting window around each injection because food blunts the GH pulse, bedtime timing to ride the first-sleep GH surge, and IGF-1 and glucose monitoring. It lists the common vial ratios as 5/5 and 10/3 and states that the combination for body composition is not backed by trials, with tesamorelin's data confined to HIV-associated lipodystrophy. Published August 2026. | |||||
| Community mixing guide: water volume and the fixed ratio | 1-3 mL of bacteriostatic water per vial; 12 mg of blend in 3 mL gives about 4 mg/mL, so the units for a 100 mcg draw depend on the chosen volume | Once, at reconstitution | Water run down the vial wall, swirled not shaken | About 30 days refrigerated after mixingNot applicable | Community resource2026 |
| Explains that adding more water lowers the concentration but cannot change the ratio of the two peptides, because the manufacturer fixed it in the powder; its table shows 12 mg of blend giving 6, 4, 3 or 2 mg/mL in 2, 3, 4 or 6 mL. It also notes that no large controlled trial has tested the combination. Published September 2026. | |||||
The most-quoted protocol starts at the full 1 mg tesamorelin plus 300 mcg ipamorelin before bed, 5 nights on and 2 off. Early reports are of water retention, vivid dreams and warmth after the injection.
The same guide places reported body-composition change from weeks 3-4, with abdominal fat change described as most visible by week 8, and says aggressive protocols add a morning half-dose in weeks 4-8.
An 8-week break follows an 8-week course in one guide; the clinic guide ends an 8-12 week cycle with a break used to recheck IGF-1 and glucose. Both describe the breaks as convention, not trial-derived.
Egrifta SV is 1.4 mg of tesamorelin once daily, continuous, with exposure matched to the 2 mg daily dose of the original 1 mg-vial Egrifta used in its trials; the label has no days off, no cycles and no ipamorelin.
Plus 6 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
What sources report for each peptide on its own. In Tesamorelin / Ipamorelin Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.
This blend puts 12 mg of tesamorelin and 3 mg of ipamorelin in one vial, a 4:1 GHRH to GHRP ratio. It is a vendor stack marketed for growth hormone release and abdominal fat loss on the back of tesamorelin's Egrifta licence; the 12/3 vial is sold by one vendor, while another sells 8/2 and others 10/3, 13/3 or 5/5, so the ratio depends on the label. No study has tested tesamorelin with ipamorelin, tesamorelin's once-daily Egrifta dose for HIV-associated lipodystrophy is the only licensed dose of any component, and the community guides below were written for the 10/3 and 5/5 vials rather than this exact one.
Fixed-ratio blend reference
Kept separate from single-peptide evidence and terminology.
Structured review queued
No evidence level is assigned until references and study models are reviewed.
Advanced Blend workspace
Calculator access performs arithmetic; it does not establish an amount or protocol.
No reviewed observation on file
The vial label remains the authoritative source for any calculation.
Each number is the vial amount for that component. It is not a per-draw amount.
3 curated references, each with its journal, year and study model, plus 6 community resources reported but not linked.